Rigel Pharmaceuticals Inc (STU:RI2A)
€ 0.878 0.002 (0.24%) Market Cap: 157.65 Mil Enterprise Value: 167.84 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

Rigel Pharmaceuticals Inc To Discuss The FDA Approval of REZLIDHIA Call Transcript

Dec 01, 2022 / 11:30PM GMT
Release Date Price: €0.6348 (-3.85%)
Operator

Greetings, and welcome to the Rigel Pharmaceuticals conference call to discuss the approval of REZLIDHIA. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to introduce our first speaker, Dean Schorno, Rigel's Chief Financial Officer. Thank you, Dean. You may begin.

Dean L. Schorno
Rigel Pharmaceuticals, Inc. - Executive VP & CFO

Welcome, and thank you for joining us today to discuss the U.S. FDA approval of REZLIDHIA. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory and product development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent annual report on Form 10-K for the year ended December 31, 2021 and subsequent filings with the SEC, including our Q3 quarterly report on Form 10-Q on file with the SEC. Any forward-looking statements are made only as of today's date, and we undertake

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot